Teropavimab

DB18916InvestigationalProtein Based Therapies

Teropavimab is under investigation in clinical trial NCT05729568 (A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection).

Mechanism: Pharmacologically active on Envelope glycoprotein gp160
Curator reviewed
Also known as: Immunoglobulin g1 (434-leucine,440-serine), anti-(human immunodeficiency virus 1 envelope protein gp120env) (human monoclonal 8c11-62a12 .gamma.1-chain), disulfide with human monoclonal 8c11-62a12 .kappa.-chain, dimer
Code names: 3BNC117 · 3BNC117-LS

Resolves to

Compound

UNII6MQW0DZ370CAS2417213-72-8

Targets

P12488env

What you can answer from here — as of July 27, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

22Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Teropavimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account